BioCentury
ARTICLE | Clinical News

Trabedersen: Phase II start

March 4, 2013 8:00 AM UTC

Next half, Antisense will begin a 2-stage Phase II trial to evaluate systemic IV trabedersen in patients with malignant melanoma, pancreatic cancer and other tumors. The first stage includes a dose-confirmatory component, while the second stage will compare trabedersen vs. standard chemotherapy for 1-2 "key" tumor indications in a larger population. ...